inpefa (sotagliflozin):INPEFA® (Sotagliflozin) Receives Preferred Formulary ...
INPEFA® (Sotagliflozin) Receives Preferred Formulary ...
2天前—DiscoveredusingLexicon'suniqueapproachtogenescience,INPEFA(sotagliflozin)isanoralinhibitoroftwoproteinsresponsibleforglucose ...。其他文章還包含有:「FDAUpdate」、「Inpefa(sotagliflozin)dosing,indications」、「INPEFATM(sotagliflozin)tablets」、「NowApproved」、「Once」、「SCOREDTrial」、「Sotagliflozin(Inpefa)forheartfailure」、「SotagliflozinfortheTreatmentofHeartFailure」
查看更多 離開網站FDA Update
https://www.acc.org
for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ...
Inpefa (sotagliflozin) dosing, indications
https://reference.medscape.com
Medscape - Heart failure dosing for Inpefa (sotagliflozin), frequency-based adverse effects, comprehensive interactions, contraindications, ...
INPEFATM (sotagliflozin) tablets
https://www.accessdata.fda.gov
Resume INPEFA when the patient is clinically stable and has resumed oral intake [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. 3. DOSAGE ...
Now Approved
https://www.inpefahcp.com
INPEFA™ is an inhibitor of SGLT2 and SGLT1 for patients with heart failure or patients with comorbidities and other cardiovascular risk factors.
Once
https://www.uspharmacist.com
Inpefa is classified as a dual inhibitor of both sodium-glucose cotransporter type 2 (SGLT2) and type 1 (SGLT1). Inhibiting SGLT2 diminishes ...
SCORED Trial
https://www.inpefahcp.com
INPEFA ™ is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart ...
Sotagliflozin (Inpefa) for heart failure
https://pubmed.ncbi.nlm.nih.go
Sotagliflozin (Inpefa) for heart failure. Med Lett Drugs Ther. 2023 Jul 24;65(1681):114-116. doi: 10.58347/tml.2023.1681b. PMID: 37460142; DOI ...
Sotagliflozin for the Treatment of Heart Failure
https://www.clinicaltrialsaren
INPEFA™ (sotagliflozin) is a once-daily oral tablet indicated to reduce the risk of cardiovascular death, hospitalisation for heart failure ...